Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer
Sarah P. Blagden(Churchill Hospital), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Shannon Murray, David Olmos(Spanish National Cancer Research Centre), M. Versola, J Barruiso, Rakesh Kumar Sharma(Chhatrapati Shahu Ji Maharaj University), Deborah A. Smith(Research Triangle Park Foundation), Mohammed M. Dar(Queen's University Belfast), Hanine Medani(Queen's University Belfast)
European Journal of Cancer Supplements
January 1, 2008
Cited by 2
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k